Compositions comprising lentiviral vectors expressing il-12 and methods of use thereof
AssigneeImmune Design Corp.
InventorsJan Henrik Ter Meulen, Peter Lars Aksel Berglund, Tinglan Tina Albershardt
Life of this patent
Estimating the term…
Abstract
This patent application relates generally to the treatment of cancer, and more particularly to the use of a pseudotyped lentivirus expressing IL-12 for the treatment of cancer.
Claims47
A method of treating cancer comprising administering intratumorally a composition comprising a dendritic cell-targeting lentiviral vector particle wherein the particle comprises a lentiviral vector genome comprising a polynucleotide sequence encoding IL-12.
(canceled)
A method of treating cancer in a subject comprising administering a product comprising:
- (a) a first composition a dendritic cell-targeting lentiviral vector particle comprising a lentiviral vector genome comprising a sequence encoding IL-12;
- and (b) a second composition comprising a second lentiviral vector particle encoding a tumor antigen;
- wherein the first composition is administered intratumorally and the second composition is administered by a different route.
(canceled)
A lentiviral vector particle comprising:
- a. an envelope comprising a Sindbis virus E2 glycoprotein of SEQ ID NO:
- 1 in which 160X is absent or is an amino acid other than glutamic acid, or a variant of SEQ ID NO:
- 1 thereof having at least 80% identity to SEQ ID NO:
- 1 and in which 160X is absent or is an amino acid other than glutamic acid, capable of infecting dendritic cells;
- wherein E2 is not part of a fusion protein with Sindbis virus E3;
- and
- b. a lentiviral vector genome comprising a polynucleotide sequence encoding IL-12.
(canceled)
(canceled)
Dependencies are inferred from the claim text.